David P. Richman

University of California, Davis — United States

Medicine · Health Sciences

43h-index7.9kcitations150works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Myasthenia Gravis and Thymoma(81), Peripheral Neuropathies and Disorders(40), Monoclonal and Polyclonal Antibodies Research(24), Ion channel regulation and function(17), Nicotinic Acetylcholine Receptors Study(17)

Publications149 total

Neuromuscular complications associated with cancer immunotherapy
Journal of the National Cancer Center·2025Open Access
Author Correction: Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells
Nature Biotechnology·2024· 1 citedOpen Access
Intravenous immunoglobulin is safe and effective in controlling pre-existing paraneoplastic neuromuscular diseases in cancer patients treated with immune checkpoint inhibitors: two case reports and literature review
Frontiers in Oncology·2023· 4 citedOpen Access
3,4‐diaminopyridine base effectively treats the weakness of Lambert‐Eaton myasthenia
2023
Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells
Nature Biotechnology·2023· 151 citedOpen Access
Enrichment of serum IgG4 in MuSK myasthenia gravis patients
Journal of Neuroimmunology·2022· 10 citedOpen Access
Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study
Proceedings of the National Academy of Sciences·2022· 124 citedOpen Access
Thymectomy and myasthenia gravis
Proceedings of the National Academy of Sciences·2020· 12 citedOpen Access
International Consensus Guidance for Management of Myasthenia Gravis
Neurology·2020· 664 citedOpen Access
Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America
BMJ Open·2020· 20 citedOpen Access
Muscle-Specific Kinase Myasthenia Gravis
Frontiers in Immunology·2020· 46 citedOpen Access
Clinical Features and Disease Management in Adult Patients With Atopic Dermatitis Receiving Care at Reference Hospitals in Brazil: the ADAPT Study
Journal of Investigational Allergology and Clinical Immunology·2020· 19 citedOpen Access
Validation of the triple timed up‐and‐go test in Lambert‐Eaton myasthenia
Muscle & Nerve·2019· 8 citedOpen Access
Immune Checkpoint Inhibitor-Induced Myasthenia Gravis in a Patient with Advanced NSCLC and Remote History of Thymoma
Clinical Lung Cancer·2019· 11 cited
Reply to Bragdon
2018
Reply
Muscle & Nerve·2018· 1 citedOpen Access
Reply: 3,4-diaminopyridine in LEMS: Concerns regarding presentation of previous studies
IUScholarWorks (Indiana University)·2018
3,4‐diaminopyridine base effectively treats the weakness of Lambert‐Eaton myasthenia
Muscle & Nerve·2017· 48 citedOpen Access
A Nicotinic Receptor Optical Biosensor
2017· 1 cited
Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator
Journal of Stroke and Cerebrovascular Diseases·2017· 13 cited
page 1 of 8Next →

Frequent Co-authors

Ricardo A. Maselli(7), Barry G.W. Arnason(7), Donald B. Sanders(6), Mark Agius(6), Christopher M. Gómez(6), Michael Nicolle(5), Gil I. Wolfe(4), Michael Benatar(4), Janice M. Massey(4), Amelia Evoli(4), Robert L. Wollmann(4), Mirta Mihovilovic(4), Arthur Melms(3), R. Malcolm Stewart(3), Zaeem A. Siddiqi(3), Carlo Provenzano(3), Roberta Ricciardi(3), Adriano Chiò(3), Henry J. Kaminski(3), Robert M. Pascuzzi(3)